Please log in, sign up for a new account and purchase a subscription to continue reading. Thank you for reading 10 free articles on our site. If you are a 7-day subscriber, you may enjoy all of our valuable local news and information at no …
Robert D. Ramnarine, the executive, was accused of buying call options in ZymoGenetics, Pharmasset and Amylin Pharmaceuticals before the companies were acquired by Bristol-Myers Squibb. Call options give their buyer the right to …
Analysts have increased the stock’s price target based on the company’s big year in clinical trial results. Bristol Myers Squibb shares were mostly flat during premarket trading Wednesday. The stock has increased 1.5% in the past year. …
Bristol-Myers--maker of such products as Ban, Excedrin and Drano--and Squibb--a prescription drug manufacturer that …
The same day Bristol-Myers Squibb shook up its board to satisfy one activist investor, the drugmaker was faced with ­another: Carl Icahn, whose interest is fuelling speculation the company could soon be put on the auction block. The …
Bristol-Myers’ rheumatoid arthritis treatment Orencia ... company as it faces a plethora of patent losses over the next few years,” Morningstar senior stock analyst Damien Conover wrote in a note to clients on Jan. 28. The first phase of work …
StockMarketWire.com - Nigel Newton, Chief Executive Officer, sold post-exercise 14,967 shares in the company on the 7th December 2016 at a price of 158.50p. The Director now holds 1,207,946 shares. NOTE: Sold to cover tax liabilities …
Major pharma companies like Eli Lilly LLY, Bristol-Myers Squibb BMY, GlaxoSmithKline plc GSK and Novartis (Read more: Novartis Q3 Earnings & Sales Top on New Drugs Strength) reported third quarter results this week. While it was …
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Bristol-Myers Squibb Company …